Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F11%3A00003290" target="_blank" >RIV/00216208:11120/11:00003290 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/11:#0000077

Result on the web

<a href="http://dx.doi.org/10.1111/j.1463-1326.2011.01382.x" target="_blank" >http://dx.doi.org/10.1111/j.1463-1326.2011.01382.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1463-1326.2011.01382.x" target="_blank" >10.1111/j.1463-1326.2011.01382.x</a>

Result language

angličtina

Original language name

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Original language description

To evaluate the efficacy and safety of saxagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Methods: In this multicentre, randomized, parallel-group, double-blind, placebo-controlled study, patients with glycatedhaemoglobin (HbA1c) 7-11% and creatinine clearance <50 ml/min were stratified by baseline renal impairment (moderate, severe or end-stage on haemodialysis), and randomized (1: 1) to saxagliptin 2.5 mg once daily or placebo for 12 weeks. Oral antihyperglycaemic drugs and insulin therapy present at enrolment were continued throughout the study. The absolute change in HbA1c from baseline to week 12 (primary efficacy end-point) was analysed using an analysis of covariance model with last observation carried forward methodology. A total of 170 patients were randomized and treated. The adjusted mean decrease from baseline to week 12 in HbA1c was statistically significantly greater in the saxagliptin group than in the placebo group; the diffe

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FE - Other fields of internal medicine

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Diabetes Obesity & Metabolism

ISSN

1462-8902

e-ISSN

—

Volume of the periodical

13

Issue of the periodical within the volume

6

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

523-532

UT code for WoS article

000289731100007

EID of the result in the Scopus database

—